Browse By Keywords
WBJ Features
- Industry Lists
- Get Your Company Listed in the WBJ
- WBJ Events
- WBJ Nominations
- Submit A News Release
- Submit A Calendar Item
- New England Meetings Guide
- New Hampshire: First In The Nation
- WBJ Giving Guide 2011
- WBJ Business Profiles 2010
- WBJ's YouTube Channel
- WBJ on Twitter
- WBJ on Facebook
- WBJ on LinkedIn
- WBJ Multimedia
Ischemix LLC, a Maynard-based drug discovery company, said it has begun bringing patients into a Phase II clinical trial of a drug designed to prevent an injury that can occur during certain heart surgeries.
The privately-held company is calling the drug CMX-2043 and it is intended to prevent a condition known as ischemia-reperfusion injury. The injury is caused by temporarily insufficient blood flow to cells in blood vessels during an elective heart surgery known as PCI.
The drug came away from its Phase I trial with an excellent safety profile, the company said.
The Phase II trial will compare three different dosing levels of the drug and further study the effects of the drug on the body.
This article does not currently have any comments